Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Tango Therapeutics, Inc. TNGX
$3.65
-$0.05 (-1.35%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
322848600.00000000
-
week52high
8.56
-
week52low
3.10
-
Revenue
24860000
-
P/E TTM
-3
-
Beta
1.63610700
-
EPS
-1.19000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | 20 сент 2021 г. | |
| Wedbush | Outperform | 07 сент 2021 г. | |
| Guggenheim | Buy | 07 сент 2021 г. | |
| Goldman Sachs | Buy | 07 сент 2021 г. | |
| HC Wainwright & Co. | Buy | 20 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Weitzman Aaron | A | 350000 | 350000 | 01 дек 2022 г. |
| Boxer Capital, LLC | A | 7123642 | 70000 | 13 окт 2022 г. |
| Boxer Capital, LLC | A | 268524 | 50000 | 12 окт 2022 г. |
| Boxer Capital, LLC | A | 218524 | 117000 | 11 окт 2022 г. |
| Boxer Capital, LLC | A | 7053642 | 70394 | 06 окт 2022 г. |
| Boxer Capital, LLC | A | 6983248 | 40500 | 05 окт 2022 г. |
| Boxer Capital, LLC | A | 6942748 | 45500 | 05 окт 2022 г. |
| Boxer Capital, LLC | A | 6897248 | 25606 | 04 окт 2022 г. |
| Borisy Alexis | A | 40000 | 40000 | 08 июн 2022 г. |
| Davis Aaron I. | A | 40000 | 40000 | 08 июн 2022 г. |
Новостная лента
Tango Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
02 февр 2023 г. в 07:00
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in February.
Tango Therapeutics: Upcoming Proof Of Concept Data Is A Major Catalyst
Seeking Alpha
27 янв 2023 г. в 15:30
Tango Therapeutics' SPAC entry to the market and Gilead deal has put a large dollar figure besides its name. Tango has an upcoming proof of concept data readout that should validate its platform.
Tango Therapeutics: Behind The Recent Momentum
Seeking Alpha
14 ноя 2022 г. в 16:11
Shares of early clinical-stage biotech Tango Therapeutics, Inc. are down ~50% since going public in August 2021 – primarily victimized by a lack of catalysts and a tough market. However, the shares have rallied strongly over the past month.
Tango Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
07 ноя 2022 г. в 07:00
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in November.
Why Tango Therapeutics Shares Rose 39.7% This Week
The Motley Fool
21 окт 2022 г. в 17:14
The clinical-stage biotech company has two candidates in its drug pipeline.